<SEC-DOCUMENT>0001140361-25-004890.txt : 20250214
<SEC-HEADER>0001140361-25-004890.hdr.sgml : 20250214
<ACCEPTANCE-DATETIME>20250214170934
ACCESSION NUMBER:		0001140361-25-004890
CONFORMED SUBMISSION TYPE:	SCHEDULE 13G
PUBLIC DOCUMENT COUNT:		1
FILED AS OF DATE:		20250214
DATE AS OF CHANGE:		20250214

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Marker Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001094038
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				880277072
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13G
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	005-58217
		FILM NUMBER:		25630757

	BUSINESS ADDRESS:	
		STREET 1:		2450 HOLCOMBE BLVD
		STREET 2:		SUITE BCM-A, MS: BCM251
		CITY:			HOUSTON
		STATE:			TX
		ZIP:			77021
		BUSINESS PHONE:		(713) 400-6400

	MAIL ADDRESS:	
		STREET 1:		2450 HOLCOMBE BLVD
		STREET 2:		SUITE BCM-A, MS: BCM251
		CITY:			HOUSTON
		STATE:			TX
		ZIP:			77021

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	TAPIMMUNE INC.
		DATE OF NAME CHANGE:	20170629

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	TAPIMMUNE INC
		DATE OF NAME CHANGE:	20070628

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	GENEMAX CORP
		DATE OF NAME CHANGE:	20020718

FILED BY:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Blue Owl Capital Holdings LP
		CENTRAL INDEX KEY:			0001858703
		ORGANIZATION NAME:           	
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13G

	BUSINESS ADDRESS:	
		STREET 1:		399 PARK AVENUE
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10022
		BUSINESS PHONE:		212-287-6787

	MAIL ADDRESS:	
		STREET 1:		399 PARK AVENUE
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10022
</SEC-HEADER>
<DOCUMENT>
<TYPE>SCHEDULE 13G
<SEQUENCE>1
<FILENAME>primary_doc.xml
<TEXT>
<XML>
<?xml version="1.0" encoding="UTF-8"?><edgarSubmission xmlns="http://www.sec.gov/edgar/schedule13g" xmlns:com="http://www.sec.gov/edgar/common">
<headerData>
<submissionType>SCHEDULE 13G</submissionType>
<filerInfo>
<filer>
<filerCredentials>
<cik>0001858703</cik>
<ccc>XXXXXXXX</ccc>
</filerCredentials>
</filer>
<liveTestFlag>LIVE</liveTestFlag>



</filerInfo>
</headerData>
<formData>
<coverPageHeader>
<securitiesClassTitle>Common Stock, $0.001 par value</securitiesClassTitle>
<eventDateRequiresFilingThisStatement>12/31/2024</eventDateRequiresFilingThisStatement>
<issuerInfo>
<issuerCik>0001094038</issuerCik>
<issuerName>Marker Therapeutics, Inc.</issuerName>
<issuerCusip>57055L206</issuerCusip>
<issuerPrincipalExecutiveOfficeAddress>
<com:street1>2450 Holcombe Blvd, Suite BCM-A</com:street1>
<com:street2>MS: BCM251</com:street2>
<com:city>Houston</com:city>
<com:stateOrCountry>TX</com:stateOrCountry>
<com:zipCode>77021</com:zipCode>
</issuerPrincipalExecutiveOfficeAddress>
</issuerInfo>
<designateRulesPursuantThisScheduleFiled>
<designateRulePursuantThisScheduleFiled>Rule 13d-1(b)</designateRulePursuantThisScheduleFiled>
</designateRulesPursuantThisScheduleFiled>
</coverPageHeader>
<coverPageHeaderReportingPersonDetails>

<reportingPersonName>Blue Owl Capital Holdings LP</reportingPersonName>
<citizenshipOrOrganization>DE</citizenshipOrOrganization>
<reportingPersonBeneficiallyOwnedNumberOfShares>
<soleVotingPower>554250</soleVotingPower>
<sharedVotingPower>0</sharedVotingPower>
<soleDispositivePower>554250</soleDispositivePower>
<sharedDispositivePower>0</sharedDispositivePower>
</reportingPersonBeneficiallyOwnedNumberOfShares>
<reportingPersonBeneficiallyOwnedAggregateNumberOfShares>554250</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>
<aggregateAmountExcludesCertainSharesFlag>N</aggregateAmountExcludesCertainSharesFlag>
<classPercent>5.18</classPercent>
<typeOfReportingPerson>PN</typeOfReportingPerson>
<comments>The reported percentage is calculated based on 10,707,295 shares of common stock outstanding as of January 17, 2025, as reported on the Issuer's Prospectus filed with the Securities and Exchange Commission on January 17, 2025.</comments>
</coverPageHeaderReportingPersonDetails>
<items>
<item1>
<issuerName>Marker Therapeutics, Inc.</issuerName>
<issuerPrincipalExecutiveOfficeAddress>2450 Holcombe Blvd, Suite BCM-A, MS: BCM251, Houston, Texas, 77021</issuerPrincipalExecutiveOfficeAddress>
</item1>
<item2>
<filingPersonName>Blue Owl Capital Holdings LP, referred to herein as the "Reporting Person."</filingPersonName>
<principalBusinessOfficeOrResidenceAddress>399 Park Avenue
New York, NY 10022</principalBusinessOfficeOrResidenceAddress>
<citizenship>See response to Item 4 on the cover page.</citizenship>
</item2>
<item3>
<notApplicableFlag>N</notApplicableFlag>
<typeOfPersonFiling>IA</typeOfPersonFiling>
</item3>
<item4>
<amountBeneficiallyOwned>See response to Item 9 on the cover page.

Pursuant to Rule 13d-4 of the Act, the Reporting Persons declare that filing this statement on Schedule 13G (this "Statement") shall not be construed as an admission that any of the Reporting Persons are, for the purposes of Section 13(d) and/or Section 13(g) of the Act, the beneficial owner of any securities covered by this Statement, and such beneficial ownership is expressly disclaimed by each Reporting Person.</amountBeneficiallyOwned>
<classPercent>See response to Item 11 on the cover page.</classPercent>
<numberOfSharesPersonHas>
<solePowerOrDirectToVote>See response to Item 5 on the cover page.</solePowerOrDirectToVote>
<sharedPowerOrDirectToVote>See response to Item 6 on the cover page.</sharedPowerOrDirectToVote>
<solePowerOrDirectToDispose>See response to Item 7 on the cover page.</solePowerOrDirectToDispose>
<sharedPowerOrDirectToDispose>See response to Item 8 on the cover page.</sharedPowerOrDirectToDispose>
</numberOfSharesPersonHas>
</item4>
<item5>
<notApplicableFlag>Y</notApplicableFlag>
</item5>
<item6>
<notApplicableFlag>Y</notApplicableFlag>
</item6>
<item7>
<notApplicableFlag>Y</notApplicableFlag>
</item7>
<item8>
<notApplicableFlag>Y</notApplicableFlag>
</item8>
<item9>
<notApplicableFlag>Y</notApplicableFlag>
</item9>
<item10>
<notApplicableFlag>N</notApplicableFlag>
<certifications>By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.</certifications>
</item10>
</items>
<signatureInformation>
<reportingPersonName>Blue Owl Capital Holdings LP</reportingPersonName>
<signatureDetails>
<signature>/s/ Karen Hager</signature>
<title>Karen Hager, Chief Compliance Officer</title>
<date>02/14/2025</date>
</signatureDetails>
</signatureInformation>
</formData>
</edgarSubmission>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
